Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Activity of secukinumab, an anti‒IL-17A antibody, on brain lesions in RRMS: Results from a randomized, proof-of-concept study

Havrdova, Eva and Belova, Anna and Goloborodko, Alla and Tisserant, Anne and Wright, Andrew and Wallstroem, Erik and garren, hideki and Maguire, Paul and Johns, Donald (2016) Activity of secukinumab, an anti‒IL-17A antibody, on brain lesions in RRMS: Results from a randomized, proof-of-concept study. Journal of Neurology.

Abstract

We assessed the effect of secukinumab on numbers of new active brain magnetic resonance imaging (MRI) lesions in subjects with relapsing-remitting multiple sclerosis (MS). Subjects (n=73) were randomized 1:1 to secukinumab 10 mg/kg or placebo by IV infusion at Weeks 0, 2, 4, 8, 12, 16, and 20. Compared with placebo, secukinumab reduced combined unique active lesions (CUAL) observed on 4-weekly MRI from Week 4 to 24 by 49% (95% CI, -10% to 77%; P=0.087) and cumulative new gadolinium-enhancing T1 lesions by 67% (31% to 84%, P=0.003). CUAL reductions were progressively greater from Week 4 (1%) to Week 16 (49%) and persisted until end-study (50%). There were no serious adverse events (SAEs); the AE rate was comparable to placebo (53% versus 49%), although infection was somewhat more frequent (37% versus 23%). Secukinumab was associated with reduced MRI lesion activity and was safe/well tolerated, supporting further clinical development in MS.

Item Type: Article
Keywords: RRMS, multiple sclerosis, neuroscience, AIN457, sekukinumab,
Date Deposited: 10 May 2016 23:45
Last Modified: 10 May 2016 23:45
URI: https://oak.novartis.com/id/eprint/22380

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.